Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Phototherapy | 5 | 2016 | 368 | 1.530 |
Why?
|
| Laser Therapy | 6 | 2024 | 1108 | 1.180 |
Why?
|
| Photochemotherapy | 3 | 2016 | 828 | 0.930 |
Why?
|
| Blepharoptosis | 1 | 2023 | 144 | 0.760 |
Why?
|
| Eyelid Diseases | 1 | 2023 | 155 | 0.730 |
Why?
|
| Skin Diseases, Vascular | 1 | 2016 | 41 | 0.510 |
Why?
|
| Rosacea | 1 | 2016 | 60 | 0.500 |
Why?
|
| Iontophoresis | 1 | 2015 | 74 | 0.480 |
Why?
|
| Foot Dermatoses | 1 | 2013 | 46 | 0.440 |
Why?
|
| Ultraviolet Therapy | 1 | 2013 | 82 | 0.430 |
Why?
|
| Onychomycosis | 1 | 2013 | 50 | 0.430 |
Why?
|
| Hyperpigmentation | 1 | 2015 | 116 | 0.430 |
Why?
|
| Skin Diseases | 2 | 2024 | 1083 | 0.410 |
Why?
|
| Tretinoin | 1 | 2015 | 524 | 0.380 |
Why?
|
| Lasers, Solid-State | 1 | 2013 | 183 | 0.370 |
Why?
|
| Adipose Tissue | 3 | 2021 | 3314 | 0.360 |
Why?
|
| Acne Vulgaris | 1 | 2016 | 352 | 0.360 |
Why?
|
| Skin Aging | 2 | 2015 | 140 | 0.350 |
Why?
|
| Lasers, Semiconductor | 1 | 2009 | 44 | 0.330 |
Why?
|
| Photosensitizing Agents | 1 | 2013 | 627 | 0.320 |
Why?
|
| Water | 1 | 2015 | 1417 | 0.310 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2009 | 91 | 0.310 |
Why?
|
| Dermatologic Agents | 2 | 2015 | 314 | 0.310 |
Why?
|
| Primary Prevention | 1 | 2016 | 1186 | 0.310 |
Why?
|
| Erythema Multiforme | 1 | 2007 | 31 | 0.280 |
Why?
|
| Pigmentation Disorders | 1 | 2007 | 105 | 0.260 |
Why?
|
| Hair Removal | 1 | 2005 | 41 | 0.240 |
Why?
|
| Cosmetic Techniques | 2 | 2021 | 149 | 0.220 |
Why?
|
| Lasers | 2 | 2022 | 951 | 0.220 |
Why?
|
| Neurotoxins | 1 | 2023 | 240 | 0.190 |
Why?
|
| Eyelids | 1 | 2023 | 278 | 0.180 |
Why?
|
| Raynaud Disease | 1 | 2021 | 81 | 0.180 |
Why?
|
| Cytomegalovirus Infections | 1 | 2007 | 838 | 0.170 |
Why?
|
| Cryotherapy | 1 | 2021 | 164 | 0.170 |
Why?
|
| Edema | 1 | 2023 | 764 | 0.160 |
Why?
|
| Treatment Outcome | 8 | 2024 | 65202 | 0.130 |
Why?
|
| Lentigo | 1 | 2015 | 37 | 0.120 |
Why?
|
| Melanosis | 1 | 2015 | 93 | 0.110 |
Why?
|
| Porphyrins | 1 | 2015 | 352 | 0.110 |
Why?
|
| Single-Blind Method | 1 | 2015 | 1587 | 0.090 |
Why?
|
| Education, Medical, Continuing | 1 | 2016 | 829 | 0.090 |
Why?
|
| Dermis | 1 | 2009 | 203 | 0.070 |
Why?
|
| Massage | 1 | 2008 | 84 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2016 | 24272 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2009 | 877 | 0.070 |
Why?
|
| Foscarnet | 1 | 2007 | 36 | 0.070 |
Why?
|
| Suction | 1 | 2008 | 268 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 4049 | 0.070 |
Why?
|
| Infrared Rays | 1 | 2008 | 246 | 0.070 |
Why?
|
| Radio Waves | 1 | 2008 | 245 | 0.070 |
Why?
|
| Epidermis | 1 | 2009 | 540 | 0.070 |
Why?
|
| Ganciclovir | 1 | 2007 | 256 | 0.070 |
Why?
|
| Pancytopenia | 1 | 2007 | 102 | 0.060 |
Why?
|
| Administration, Cutaneous | 1 | 2008 | 712 | 0.060 |
Why?
|
| Obesity | 1 | 2008 | 13088 | 0.060 |
Why?
|
| Humans | 16 | 2024 | 766432 | 0.060 |
Why?
|
| Optical Devices | 1 | 2005 | 34 | 0.060 |
Why?
|
| Swine | 1 | 2015 | 5981 | 0.060 |
Why?
|
| Bone Marrow Diseases | 1 | 2007 | 234 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 39283 | 0.060 |
Why?
|
| Equipment Safety | 1 | 2005 | 250 | 0.060 |
Why?
|
| Patient Satisfaction | 2 | 2007 | 3485 | 0.050 |
Why?
|
| Esthetics | 1 | 2005 | 328 | 0.050 |
Why?
|
| Female | 11 | 2021 | 396354 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 5860 | 0.050 |
Why?
|
| Antiviral Agents | 2 | 2022 | 3068 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2007 | 1838 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2015 | 5988 | 0.050 |
Why?
|
| Middle Aged | 7 | 2021 | 223127 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2022 | 769 | 0.040 |
Why?
|
| Equipment Design | 1 | 2005 | 3481 | 0.030 |
Why?
|
| Hepatitis C | 1 | 2007 | 1595 | 0.030 |
Why?
|
| Adult | 6 | 2022 | 223253 | 0.030 |
Why?
|
| Prognosis | 2 | 2016 | 29922 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8536 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 3690 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2009 | 8720 | 0.030 |
Why?
|
| Male | 5 | 2021 | 363975 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2007 | 2417 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2021 | 2653 | 0.030 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 1083 | 0.030 |
Why?
|
| Pain | 1 | 2009 | 5097 | 0.030 |
Why?
|
| Skin | 1 | 2007 | 4498 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 1997 | 1071 | 0.020 |
Why?
|
| Young Adult | 2 | 2021 | 59928 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 1997 | 2799 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2009 | 41703 | 0.020 |
Why?
|
| Mammography | 1 | 1996 | 2430 | 0.020 |
Why?
|
| Disease Progression | 1 | 2021 | 13632 | 0.010 |
Why?
|
| Adolescent | 2 | 2022 | 88898 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 168887 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 1997 | 21157 | 0.010 |
Why?
|
| Lymphatic Metastasis | 2 | 1997 | 2900 | 0.010 |
Why?
|
| cdc25 Phosphatases | 1 | 1997 | 60 | 0.010 |
Why?
|
| Retrospective Studies | 3 | 2021 | 81588 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 1997 | 316 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 59538 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1997 | 327 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 1997 | 629 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 1997 | 661 | 0.010 |
Why?
|
| Axilla | 1 | 1996 | 622 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1997 | 1887 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1997 | 1058 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 1997 | 1159 | 0.010 |
Why?
|
| Aged | 2 | 2021 | 171234 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 1996 | 784 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 1996 | 1267 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 1997 | 2251 | 0.000 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 1996 | 1097 | 0.000 |
Why?
|
| Neoplasm Invasiveness | 1 | 1996 | 3608 | 0.000 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1997 | 2947 | 0.000 |
Why?
|
| Receptor, erbB-2 | 1 | 1997 | 2597 | 0.000 |
Why?
|
| Cell Cycle Proteins | 1 | 1997 | 3439 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 1997 | 11059 | 0.000 |
Why?
|
| Neoplasm Staging | 1 | 1996 | 11217 | 0.000 |
Why?
|
| Age Factors | 1 | 1997 | 18395 | 0.000 |
Why?
|
| Mass Screening | 1 | 1996 | 5451 | 0.000 |
Why?
|
Concepts
(117)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(10)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_